Trifunctional purine biosynthetic protein adenosine-3 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Trifunctional purine biosynthetic protein adenosine-3 shows approved-linked disease relevance led by mesothelioma. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P22102. Start with mesothelioma, then reuse UniProt P22102 as the stable protein anchor across project notes and exports.
Start with mesothelioma, then reuse UniProt P22102 as the stable protein anchor across project notes and exports.
Trifunctional purine biosynthetic protein adenosine-3 shows approved-linked disease relevance led by mesothelioma. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with mesothelioma because it currently carries approved-linked support. Linked drugs include PEMETREXED, PEMETREXED DISODIUM, PEMETREXED MONOHYDRATE, PEMETREXED TROMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTrifunctional purine biosynthetic protein adenosine-3
Review this target as Trifunctional purine biosynthetic protein adenosine-3, mapped to UniProt P22102. Sequence length is 1010 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Trifunctional purine biosynthetic protein adenosine-3 as ChEMBL target CHEMBL3972, mapped to UniProt P22102. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Trifunctional purine biosynthetic protein adenosine-3 is the right protein anchor across sources, using UniProt P22102 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why mesothelioma is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Trifunctional purine biosynthetic protein adenosine-3 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P22102 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Trifunctional purine biosynthetic protein adenosine-3 |
| UniProt Accession | P22102 |
| Component Type | Protein |
| Sequence Length | 1010 aa |
Trifunctional purine biosynthetic protein adenosine-3
Review this target as Trifunctional purine biosynthetic protein adenosine-3, mapped to UniProt P22102. Sequence length is 1010 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Trifunctional purine biosynthetic protein adenosine-3 shows approved-linked disease relevance led by mesothelioma. 5 more disease programs remain visible in the same review block.
Start review with mesothelioma because it currently carries approved-linked support. Linked drugs include PEMETREXED, PEMETREXED DISODIUM, PEMETREXED MONOHYDRATE, PEMETREXED TROMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL279302 | 10.85 | IC50 | 0.014 | Preclinical |
| CHEMBL4643623 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL4437824 | 9.49 | IC50 | 0.32 | Preclinical |
| CHEMBL2158681 | 9.22 | IC50 | 0.6 | Preclinical |
| CHEMBL4465095 | 9.15 | IC50 | 0.7 | Preclinical |
| CHEMBL4636872 | 9.02 | IC50 | 0.95 | Preclinical |
| CHEMBL192632 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL3628344 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4538151 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4445651 | 8.92 | IC50 | 1.2 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 70 | 57 | 6.6 |
| cell-based format | 30 | 49 | 8.0 |
| assay format | 6 | 27 | 5.4 |
| tissue-based format | 2 | 7 | 5.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 2 | 0 | — |
| cell-based format | 2 | 1 | 7.8 |